Fra-1 Promotes Breast Cancer Chemosensitivity by Driving Cancer Stem Cells from Dormancy

Dan Lu¹,², Si Chen¹, Xiaoyue Tan¹, Na Li¹, Chenghu Liu¹, Zongjin Li¹, Ze Liu¹, Dwayne G. Stupack³, Ralph A Reisfeld², and Rong Xiang¹

Authors Affiliations: ¹ School of Medicine, Nankai University, Tianjin, China; ² The Scripps Research Institute, La Jolla, CA, USA, and ³ UCSD School of Medicine & The Moores UCSD Cancer Center, La Jolla, CA, USA

Running Title: Fra-1 drive breast cancer cells from dormancy

Keywords: Fra-1, breast cancer, cancer stem cells, chemosensitivity, tumor dormancy

Note: Dan Lu and Si Chen contributed equally to this work.

Corresponding Author: Rong Xiang, School of Medicine, Nankai University, 94 Weijin Road, Tianjin 300071, China. Phone: 86-22-2350-9505; Email: rxiang@nankai.edu.cn. Ralph A. Reisfeld, Department of Immunology and Microbial Science, The Scripps
Disclosure of Potential Conflicts of Interest: No potential conflicts of interest were disclosed.
Abstract

Fra-1 is a member of the Fos transcription factor family that is highly expressed in multiple cancers, playing important roles in transformation, proliferation and metastasis. In this study, we observed an inverse correlation between the expression of Fra-1 in human stage II breast cancer tissues and the corresponding level of clinical chemoresistance. Extending these findings in vitro, we found that knockdown of Fra-1 in breast tumor cells was sufficient to confer resistance to doxorubicin and cyclophosphamide, while enhanced Fra-1 expression could render these cells chemosensitive. The tumor cell 'side population' (SP), which is enriched for cancer stem-like cells, was found to be associated with chemoresistance. Increased SP fractions were detected among tumor cell lines subjected to Fra-1 knockdown. In contrast, enhanced expression of Fra-1 was correlated with a decreased SP fraction, and significantly, this finding was recapitulated in vivo, where tumors with enhanced expression of Fra-1 were found to have blunted growth. Tumor cells subjected to Fra-1 knockdown grew faster and were larger in size. Taken together, our findings suggest that Fra-1 may be an important prognostic marker for breast cancer therapy.
Introduction

Chemotherapy has become a routine therapeutic approach for the treatment of cancer, with significant impact on patient survival. Nonetheless, many unsolved issues remain which lead to dose limiting toxicities of chemotherapy. Among these, cancer relapse and emerging drug resistance remain key factors determining chemotherapeutic efficacy.

The cancer stem cell hypothesis suggests that a small population of cells within a tumor will tend to share some common features with stem or progenitor cells, including self-renewal and differentiation. These cancer stem-like cells (CSCs) are thought to be responsible not only for primary tumorigenesis, but also for resistance to chemotherapy and subsequent cancer recurrence. A variety of mechanisms have been proposed to contribute to CSC chemoresistance, including relative quiescence, expression of ATP-binding cassette (ABC) transporters and/or multidrug resistance transporter 1 (MDR1), a more robust DNA repair capability, and the elevated expression of anti-apoptotic proteins (1). All of these natural characteristics combine to make CSCs a particularly challenging target for chemotherapy (2, 3).

The Fos family transcription factor Fra-1 has weak transforming activity, due largely to its lack of potent transactivation domains. Fra-1 typically heterodimerizes with Jun family members (c-Jun, JunB or JunD) to form the AP-1 (activator protein-1) transcription factor complex. Initially identified as an immediate early transcriptional response element following exposure to serum (4), Fra-1 was later found to exhibit transforming activity in rat fibroblasts (5) and thyroid cells (6). Recent studies have suggested Fra-1 to be involved in tumorigenesis and cancer progression, with elevated
Fra-1 expression detected in breast (7), lung (8), brain (9), colon (10) and prostate cancers (11). Functionally, Fra-1 expression promoted tumor cell proliferation, inhibited apoptosis, and increased cell invasion (12).

Here, we examined Fra-1 for its role in breast cancer progression via its potential effect on CSCs. Unexpectedly, we found that immunohistochemical (IHC) staining of human stage II breast cancer tissues supported a significant correlation between the expression of Fra-1 and patients' response to chemotherapy and outcome. When we directly tested the function of Fra-1 in breast cancer CSCs, we found that suppression of Fra-1 expression correlated with both an increase in tumor CSCs and a concurrent increase in chemoresistance, while ectopic Fra-1 expression correlated with decreased incidence of CSCs and increased chemosensitivity of murine breast cancer cells. Together, these results suggest a novel role for Fra-1 in cancer biology, and raise the possibility that Fra-1 may be a significant prognostic response marker for tumor therapy.
Materials and Methods

Animals, cell lines and tissue samples

Female Balb/c mice, 6-8 weeks of age, were purchased from The Scripps Research Institute Rodent Breeding Facility (La Jolla, CA, USA). All animal experiments and protocols were performed according to the NIH Guide for the Care and Use of Laboratory Animals and approved by The Scripps Research Institute Animal Care Committee. Murine breast cancer cell line 4TO7 was kindly provided by Suzanne Ostrand-Rosenberg (University of Maryland, College Park, Maryland, USA). Human 293T cells were a gift from Wen-yuan Hu (Biosettia). A total of 63 Stage II breast cancer samples were collected at the Cancer Institute and Hospital of Tianjin Medical University after informed consents had been obtained from all patients.

Lentiviral transduction systems

Murine Fra-1 cDNA was generated by PCR-based amplification with the following primer set: forward primer: 5’-GGCCTCTAGAGCCACCATGTACCAGACTACGGGGAACCGGGACCG-3’, reverse primer: 5’-GGCCGGATCCTCACAAAGCCAGGAGTGTAGGAGAGCCCAG-3’, and cloned into XbaI and BamHI restriction sites of pLV-EF1α-MCS-IRES-Bsd expression vector (Biosettia). Three helper plasmids, pMDLg/pRRE, pRSV-REV and pCMV-VSV-G were kindly provided by Wen-yuan Hu (Biosettia). shRNAs of Fra-1 were inserted into pLV-H1-EF1α-puro vector (Biosettia). Sequences of the hairpins and the scramble control (SC) vector are the followings:

shRNA1:

AAAAGTTCCACCTTGTGCCAAGCATTTGGATCCAAATGCTTGGCACAAGGTGGAAC
shRNA2:

AAAAGAAAGGAGCTGACAGACTTCTTGATCCAAGAAGTCTGTCAGCTCCTTTC

Scr-shRNA:

AAAAGCTACACTATCGAGCAATTTTGGATCCAAAATTGCTCGATAGTGTAGC

Lentiviruses were generated from 293T cells according to the protocol of Single Oligonucleotide RNAi Technology for Gene Silencing (Biosettia). Stable 4TO7 cells were selected by Blasticidin (Invitrogen) or Puromycin (Sigma-Aldrich) 48 hrs after lentiviral transduction.

**HOECHST 33342 dye exclusion assay**

Cells (1×10⁶/ml) were stained with 10µg/ml HOECHST 33342 (Sigma-Aldrich) with or without verapamil hydrochloride (50uM, Sigma-Aldrich). Cells were incubated at 37°C for 1 hr as described previously (13).

**Cell cycle analysis**

Cells (1×10⁶/ml) were fixed in 70% cold ethanol for 1 hr, then incubated in ice-cold PBS containing 50µg RNase A (QIAGEN) at 37°C for 1 hr. Cells were treated with 10 µg of PI (10µg/ml, Molecular Probes), incubated at 4°C overnight, and data collected on the next day.

**Protein expression analysis**

Protein expression of Fra-1 was demonstrated by immunoblotting using antibodies (Abs) from Santa Cruz (anti-murine Fra-1, anti-murine β-actin, Goat anti-Rabbit IgG HRP and Goat anti-mouse IgG-HRP). To detect expression of Sca-1, 10⁶ cells were harvested and incubated for 1hr at 4°C in 100µl of ice-cold FACS buffer with FITC
conjugated anti-Sca-1 (BD Pharmingen). FITC conjugated anti-rat IgG (eBioscience) was used as an isotype control. Intracellular expression of Ki-67 was measured by FACS; 10^6 cells were fixed and permeabilized following manufacturer’s instructions (eBioscience) and anti-murine Fra-1 Ab (Santa Cruz), FITC conjugated goat anti-rabbit IgG Ab (Southern Biotech) and FITC conjugated anti-Ki-67 Ab (abcam) used for staining. For histology, paraffin-embedded human tissue samples were stained with Fra-1 Ab (Santa Cruz).

**DOX extinction assay**

Cells were seeded at 1.5×10^5/well in a 12-well plate one day before DOX treatment (Sigma-Aldrich). DOX (1.5μg/ml) was added to each well at different time points (0.5, 1, 2, 4, 6, 8, 20 and 24hrs). Cells were collected at 0hr and their pumping abilities measured by FACS.

**Analysis of apoptosis**

4TO7 tumor cells were (3×10^5) were seeded in a 6-well plate and cultured for 24 hrs before drug treatment. CTX (500μM, Sigma-Aldrich) was added into each well on the following day and maintained for 24hrs prior to Annexin V and PI double staining (BD Pharmingen).

**Tumor cell challenge and CTX treatment**

Balb/c mice (n=4/group) were divided into four experimental groups. 5×10^6 4TO7 cells with Fra-1 extinction, Fra-1 overexpression or control vectors were injected s.c. to the left front flank of mice on Day 0. From Day 3 to Day 11, CTX was administered to all groups of mice by i.v. injection (30mg/kg) for a total of 5 times at 2 day intervals. Tumor
dimensions were measured in two dimensions with microcalipers every other day and tumor volume was calculated as previously described (14)

Statistics

A statistical comparison of experimental groups and controls was determined by Student’s t test. Findings were regarding as significant if 2-tailed P value were less than 0.05.
Results and Discussion

We evaluated the expression of transcription factor Fra-1 within a panel of 63 paraffin-embedded tissue samples from Stage II breast cancer patients who received chemotherapy following tumor resection by immunohistochemistry. Results from immunohistochemical staining were scored as negative (no Fra-1 expression), low (<75% Fra-1 positive cells, weak staining) and high (>75% Fra-1 positive cells, strong staining) (Figure 1A-C). We expected to find a correlation between increased Fra-1 expression and disease progression (7). Surprisingly, among the cohort of patients with rapid cancer recurrence (less than 3 years), there was little staining of Fra-1, with 12 of 20 patients exhibiting no detectable expression, and 8 revealing weak expression. In contrast, each of the tissues derived from patients who failed to recur for five or more years, expressed Fra-1, with 9 of 22 patients demonstrating strong expression. Patients whose disease recurred between 3 and 5 years exhibited an intermediate phenotype: 1 of 21 tissues had no detectable Fra-1, while the remaining 20 exhibited weak Fra-1 expression (Figure 1D). This trend was highly significant (p<0.001), suggesting that high Fra-1 expression may indicate a delayed tumor relapse after chemotherapy. Conversely, the complete absence of Fra-1 would seem prognostic for rapid relapse. This correlation between chemosensitivity and Fra-1 expression was further confirmed in a panel of human breast cancer cell lines (Supplemental Figure 1A, 1B).

To examine the impact of Fra-1 on breast cancer growth and cell cycle regulation, we generated stable murine breast tumor sister cell lines with either enhanced or suppressed expression of Fra-1. Fra-1 expression was significantly increased in 4TO7-Fra-1 cells, whereas Fra-1 expression was decreased by two independent shRNAs.
which created the 4TO7-sh1 and 4TO7-sh2 cell lines. An examination of growth and proliferation of these cells via Ki-67 staining (15), indicated that 4TO7-sh1 and particularly 4TO7-sh2 cells revealed a significantly decreased expression of Ki-67 relative to scrambled controls (Supplemental Figure 2A, #p=0.12, *p<0.05). However, Ki-67 expression was increased in 4TO7-Fra-1 cells, which exhibited enhanced Fra-1 expression (Supplemental Figure 2B, *p<0.05). During further evaluation, we assessed cell cycle progression as a function of Fra-1 expression by Fluorescence Activated Cell Sorting (FACS) analysis. Staining of nuclear DNA with propidium iodide (PI) showed that suppression of Fra-1 resulted in an increased fraction of cells in the G0/G1 population, with a concurrent decrease in incidence of cells in S and G2/M phases (Supplemental Figure 3A). Conversely, ectopic expression of Fra-1 correlated with a decrease in the G0/G1 population and increase in S and G2/M fractions relative to controls (Supplemental Figure 3B). Together, these data support prior conclusions by others (6) that Fra-1 plays a positive role in regulating breast cancer proliferation in vitro, yet was paradoxically associated with better clinical prognosis in our study.

This paradox might, however, be resolved when one considers both the relative susceptibility of highly proliferative populations to chemotherapeutic therapies currently in clinical use. For example, slowly proliferating tumor cell populations may represent a somewhat enhanced significant risk for more rapid breast cancer relapse. Accordingly, resistance to chemotherapeutic drugs is a characteristic associated with among other factors, an incidence of cancer stem-like cells (CSCs). In order to explore this, we further performed Hoechst 33342 ‘exclusion technique’ to identify populations enriched in CSCs in different 4TO7 cell lines via ‘side population’ (SP) gating protocols (16). Our
findings showed a dramatic increase in the CSC-enriched population following suppression of Fra-1 expression, which was dose-dependent according to relative Fra-1 depletion (Figure 2A, 2B), while increased expression of Fra-1 depleted these CSCs (Figure 2C, 2D). To confirm that gating of our side population indeed identified a CSC population, we co-stained for expression of Sca-1, a CSCs marker (17-19), and found it highly expressed in the gated cells (Figure 3A). Accordingly, increased staining of Sca-1 was observed in cells lacking Fra-1 expression, whereas decreased expression of Sca-1 was found in cells with enhanced Fra-1 expression (Figure 3B). Together, these data revealed a strong negative correlation between the expression of Fra-1 and the relative proportion of CSCs, raising the interesting notion that Fra-1 may promote loss of CSC dormancy, and thereby enhance chemosensitivity.

To verify this contention, we first tested Doxorubicin (DOX) uptake as a function of Fra-1 expression. To this end, cells were treated with DOX (1.5µg/ml) at different time points (0.5, 1, 2, 4, 6, 8, 20 and 24 hours) and the retention of DOX assessed by quantitation of fluorescence. Between 8 and 24 hours, a dramatic reduction in retention of DOX was observed in 4TO7-sh2 cells with suppressed Fra-1 expression relative to controls (Figure 4A left, **p<0.01). In contrast, at 20 and 24 hours, increased DOX was evident within 4TO7 cells with enhanced Fra-1 expression (Figure 4A right, **p<0.01). Together, these results indicate that Fra-1 expression may be associated with different sensitivities to chemotherapeutic agents.

To further extend this result, we evaluated a second commonly used breast cancer therapeutic drug, cyclophosphamide (CTX), in our breast tumor sister cell lines. As might be predicted from prior studies of DOX, a remarkably decreased number of cell
deaths was observed in 4TO7 cells with suppressed Fra-1 expression (Figure 4B left, *p<0.05), whereas more dead cells were detected in 4TO7 cells overexpressing Fra-1 (Figure 4B right, *p<0.05). Together, these findings demonstrate that the expression levels of Fra-1 do affect in vitro chemosensitivity of 4TO7 breast cancer cells.

To determine whether the effect of Fra-1 on chemosensitivity in vitro also extended to tumors growing in vivo, we seeded syngeneic female Balb/c mice with 5×10⁵ 4TO7 cells and then evaluated their response to CTX treatment. Starting on Day 3, and every two days thereafter, mice were treated i.v. with CTX (30mg/kg) and tumor sizes tracked. Mice were sacrificed on Day 23 and tumors were resected and weighted (Figure 4C). Following termination of chemotherapy, the 4TO7-sh2 group of mice exhibited enhanced tumor growth relative to control group (Figure 4D left, *p<0.05). In fact, among 4TO7 cells with enhanced Fra-1 expression, chemotherapy had a significant impact on early tumor development. While these tumors did continue to grow, they propagated at a markedly reduced rate (Figure 4D right, **p<0.01). These results also correlated with significant differences in final tumor burden (Supplemental Figure 4A, 4B) of different Fra-1 expression mice (Supplementary Figure 4C). Importantly, these in vivo data not only confirmed our in vitro observations of the impact of Fra-1 on chemosensitivity, but also suggested that Fra-1 could become a valuable clinical marker of chemosensitivity.

Together, our analysis of human clinical breast cancer tissues and our preclinical investigations demonstrate an unexpected but important finding indicating that patients with high Fra-1 expression are more likely to present with a delay in tumor relapse following chemotherapy. This is surprising because initial studies attributed an
oncogenic function of Fra-1 in multiple solid tumors including breast tumor (7-11). We also reported that Fra-1 played a crucial role in modification and maintenance of the malignant phenotype of tumor associated macrophages (TAMs) which promoted breast cancer cell survival and invasiveness (20). Thus immune therapies were targeted to Fra-1 in mice (21, 22). In contrast, our current findings reveal that breast cancer patients lacking Fra-1 are more likely to undergo a rapid tumor relapse after chemotherapy, which may make Fra-1 a valuable prognostic marker for sustained tumor chemosensitivity.
Acknowledgments: We thank K Cairns for editorial assistance and Wenyuan-Hu for molecular biology assistance. This is TSRI manuscript number IMM-21240.

Grant Support: This work was supported by grants from NCI grant 5R01CA134364-01A1(to R.A.R), Merck Serono grant SFP1645R (to R.A.R), TRDRP grant 19XT-0051(to R.A.R), NSFC grant 30830096 (to R.X.), 973 program grant 2007CB914804 (to R.X.) and TSTC grant 09ZCZDSF04000 (to R.X.).
Reference


Figure Legends

Figure 1. Immunohistochemical (IHC) staining of Fra-1 was performed in paraffin-embedded tissues from human Stage II breast cancer patients. Fra-1 staining score was defined as (A) Negative expression: no detectable Fra-1; (B) Low expression: <75% Fra-1 positive cells and weak staining; (C) High expression: >75% Fra-1 positive cells and strong staining. Scale bar for all panels=200µm. (D) A summary of all IHC results, indicating a significant association of Fra-1 expression with chemosensitivity (p<0.001).

Figure 2. Fra-1 expression modulates the proportion of SP cells by Hoechst 33342 dye exclusion assay. (A and C) FACS analysis of SP cells stained with Hoechst33342 dye in the absence (upper panels) or presence (lower panels) of the Ca^{2+} channel blocker verapamil to confirm specificity. (B and D) Percentage of SP cells was evaluated by 3 separate measurements. Error bars represent mean ± SD, *p=0.082, *p <0.05, versus control group.

Figure 3. Fra-1 expression modulates the proportion of SP cells by Sca-1 staining. (A) Sca-1 was highly expressed in SP cells compared with non-side population (NSP) cells. (B) Expression of Sca-1 was detected by FACS in 4TO7 cells with varying Fra-1 expression. A typical experiment (of three) is depicted.
Figure 4. Fra-1 expression influences chemosensitivity of 4TO7 breast cancer cells both in vitro and in vivo. The intracellular autofluorescence of Doxorubicin (DOX, 1.5µg/ml) was measured by FACS at time points (0.5hr, 1hr, 2hr, 4hr, 6hr, 8hr, 20hr, 24hr) in 4TO7 cells with Fra-1 suppression (A left) or ectopic expression (A right). Apoptosis of 4TO7 cells with Fra-1 extinction (B left) and ectopic expression (B right) was evaluated by Annexin V and PI double staining. Cells were treated with cyclophosphamide (CTX, 500µM) for 24 hrs before FACS analysis. Three independent results were calculated and shown as bar graphs. (C) Scheme depicts the in vivo experimental approach: 5×10^5 4TO7 cells, with varying Fra-1 status, were injected s.c. in the left front flank of female Balb/c mice (n=4/group) on Day 0. All mice were treated with CTX (30mg/kg) by i.v. injection (Day 3 to 11). (D, E) When 4TO7 tumor growth became visible, tumor volume was monitored and results were graphically displayed. Scale bar for both panels=100µm. Error bars represent mean ± SD, *p <0.05, **P<0.01, versus control group.
Figure 1, Lu et al.

A

B

C

D

Fra-1 expression in human breast cancer tissues

<table>
<thead>
<tr>
<th>Tumor Recurrence</th>
<th>Fra-1 Staining</th>
<th>Total</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Negative</td>
<td>Low</td>
</tr>
<tr>
<td>within 3 years</td>
<td>12</td>
<td>8</td>
</tr>
<tr>
<td>3-5 years</td>
<td>1</td>
<td>20</td>
</tr>
<tr>
<td>more than 5 years</td>
<td>0</td>
<td>13</td>
</tr>
<tr>
<td>total</td>
<td>13</td>
<td>41</td>
</tr>
</tbody>
</table>
Figure 2, Lu et al.
Figure 3, Lu et al.
**In vitro**

**A**

- Graph showing MFI over time for Scr, sh2, Fra-1, and Vector.
- Scr and sh2 show a significant increase in MFI compared to Fra-1 and Vector.

**B**

- Bar chart showing cell death percentage for Scr, sh2, Vector, and Fra-1.
- Scr shows a lower cell death percentage compared to sh2, Vector, and Fra-1.

**In vivo**

**C**

- Timeline showing challenge, chemotherapy, sacrifice, and tumor growth.
- Tumor growth is monitored from day 0 to day 23.

**D**

- Graph showing tumor volume over time for Scr, sh2, Vector, and Fra-1.
- Scr and sh2 show a significant increase in tumor volume compared to Vector and Fra-1.
Fra-1 promotes breast cancer chemosensitivity by driving cancer stem cells from dormancy

Dan Lu, Si Chen, Xiaoyue Tan, et al.

_Cancer Res_ Published OnlineFirst May 14, 2012.

<table>
<thead>
<tr>
<th>Updated version</th>
<th>Access the most recent version of this article at: doi:10.1158/0008-5472.CAN-11-2536</th>
</tr>
</thead>
<tbody>
<tr>
<td>Supplementary Material</td>
<td>Access the most recent supplemental material at: <a href="http://cancerres.aacrjournals.org/content/suppl/2012/05/14/0008-5472.CAN-11-2536.DC1">http://cancerres.aacrjournals.org/content/suppl/2012/05/14/0008-5472.CAN-11-2536.DC1</a></td>
</tr>
<tr>
<td>Author Manuscript</td>
<td>Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited.</td>
</tr>
</tbody>
</table>

E-mail alerts | Sign up to receive free email-alerts related to this article or journal. |
Reprints and Subscriptions | To order reprints of this article or to subscribe to the journal, contact the AACR Publications Department at pubs@aacr.org. |
Permissions | To request permission to re-use all or part of this article, contact the AACR Publications Department at permissions@aacr.org. |